DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
CV logo

CapsoVision, Inc. Stock Price

NasdaqCM:CV Community·US$330.3m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

CV Share Price Performance

US$6.51
2.18 (50.35%)
​
US$9.00
Fair Value
US$6.51
2.18 (50.35%)
27.7% undervalued intrinsic discount
US$9.00
Fair Value
Price US$6.51
AnalystLowTarget US$9.00
AnalystConsensusTarget US$10.50
AnalystHighTarget US$14.00
Thu, 3 Sep 26
Fair ValueUS$9.00
Share Pricen/a

CV Community Narratives

AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$9 27.7% undervalued intrinsic discount

AI Delays And Mounting R&D Costs Will Eventually Reward Capsule Endoscopy Adoption

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$10.5 38.0% undervalued intrinsic discount

Cloud And AI Capsule Endoscopy Will Reshape Long Term Prospects For This Undervalued GI Player

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$14 53.5% undervalued intrinsic discount

AI Capsule Endoscopy And Pancreatic Screening Will Transform Long Term Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
CV logo
CapsoVision
27.7% undervalued intrinsic discount

AI Delays And Mounting R&D Costs Will Eventually Reward Capsule Endoscopy Adoption

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 3 Sep
Read Narrative
CV logo
CapsoVision
38.0% undervalued intrinsic discount

Cloud And AI Capsule Endoscopy Will Reshape Long Term Prospects For This Undervalued GI Player

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Published 25 Jan
Read Narrative
CV logo
CapsoVision
53.5% undervalued intrinsic discount

AI Capsule Endoscopy And Pancreatic Screening Will Transform Long Term Prospects

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Published 11 Jan
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
CV logo

CV: AI Expansion And ATM Program Will Support Future Upside

Fair Value: US$9 27.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
CV logo

Cloud And AI Capsule Endoscopy Will Reshape Long Term Prospects For This Undervalued GI Player

Fair Value: US$10.5 38.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
CV logo

AI Capsule Endoscopy And Pancreatic Screening Will Transform Long Term Prospects

Fair Value: US$14 53.5% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet with high growth potential.

0 Risks
2 Rewards
View Full Analysis

CapsoVision, Inc. Key Details

US$13.9m

Revenue

US$6.8m

Cost of Revenue

US$7.1m

Gross Profit

US$36.9m

Other Expenses

-US$29.8m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.60
50.88%
-214.74%
0%
View Full Analysis

About CV

Founded
2005
Employees
99
CEO
Kang-Huai Wang
WebsiteView website
capsovision.com

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.

Recent CV News & Updates

User avatar
Narrative Update • Sep 03

CV: AI Expansion And ATM Program Will Support Future Upside

Analysts have raised their fair value estimate for CapsoVision from $7.00 to $9.00, citing updated assumptions for the company’s discount rate, revenue growth outlook, profit margin profile, and future P/E expectations. What’s in the News for CapsoVision CapsoVision filed a follow on equity offering for up to US$100 million in common stock through an at the market program.

Recent updates

No updates

CapsoVision, Inc. Competitors

CSTL logo

Castle Biosciences

Symbol: NasdaqGM:CSTL
Market cap: US$987.7m
CBLL logo

CeriBell

Symbol: NasdaqGS:CBLL
Market cap: US$906.9m
INMD logo

InMode

Symbol: NasdaqGS:INMD
Market cap: US$856.5m
HSTM logo

HealthStream

Symbol: NasdaqGS:HSTM
Market cap: US$851.2m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide